Literature DB >> 8331499

The effect of N-myc amplification and expression on invasiveness of neuroblastoma cells.

Y Zaizen1, S Taniguchi, S Noguchi, S Suita.   

Abstract

Most neuroblastomas with N-myc amplification, a sign of extremely poor prognosis, are extensively invasive to surrounding tissues. Therefore, we investigated the relationship between N-myc amplification and invasiveness of neuroblastoma cells, using an in-vitro assay system. Five human neuroblastoma cell lines were used for this study. IMR-32, GOTO, and DZ, all of which had N-myc amplification, showed a highly invasive capacity. In contrast, SK-N-SH without N-myc amplification showed extremely low invasiveness. ST unexpectedly showed high invasiveness in spite of the lack of N-myc amplification. Treatment of GOTO with 10(-5) mol/L all-trans-retinoic acid (RA) for 72 hours markedly decreased both N-myc expression and invasiveness. Treatment of GOTO with 2 mmol/L dibutyryl cyclic AMP (dbcAMP) for 72 hours caused a slight decrease of N-myc expression and invasiveness. These results indicate that N-myc amplification and expression might be closely related to the invasiveness of human neuroblastoma cells.

Entities:  

Mesh:

Year:  1993        PMID: 8331499     DOI: 10.1016/0022-3468(93)90321-b

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  12 in total

1.  Modulation of N-myc expression alters the invasiveness of neuroblastoma.

Authors:  L A Goodman; B C Liu; C J Thiele; M L Schmidt; S L Cohn; J M Yamashiro; D S Pai; N Ikegaki; R K Wada
Journal:  Clin Exp Metastasis       Date:  1997-03       Impact factor: 5.150

2.  Down-regulation of MYCN protein by CX-5461 leads to neuroblastoma tumor growth suppression.

Authors:  Jordan S Taylor; Jasmine Zeki; Kimberly Ornell; Jeannine Coburn; Hiroyuki Shimada; Naohiko Ikegaki; Bill Chiu
Journal:  J Pediatr Surg       Date:  2019-02-28       Impact factor: 2.545

3.  Stromal cell-derived CSF-1 blockade prolongs xenograft survival of CSF-1-negative neuroblastoma.

Authors:  Dietmar Abraham; Karin Zins; Mouldy Sioud; Trevor Lucas; Romana Schäfer; E Richard Stanley; Seyedhossein Aharinejad
Journal:  Int J Cancer       Date:  2010-03-15       Impact factor: 7.396

4.  N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma.

Authors:  J Kang; P G Rychahou; T A Ishola; J M Mourot; B M Evers; D H Chung
Journal:  Oncogene       Date:  2008-02-18       Impact factor: 9.867

5.  FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastoma.

Authors:  Michael L Megison; Jerry E Stewart; Hugh C Nabers; Lauren A Gillory; Elizabeth A Beierle
Journal:  Clin Exp Metastasis       Date:  2012-12-04       Impact factor: 5.150

Review 6.  Neuroblastoma and MYCN.

Authors:  Miller Huang; William A Weiss
Journal:  Cold Spring Harb Perspect Med       Date:  2013-10-01       Impact factor: 6.915

7.  Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma.

Authors:  Elizabeth A Beierle; Xiaojie Ma; Jerry Stewart; Carl Nyberg; Angelica Trujillo; William G Cance; Vita M Golubovskaya
Journal:  Cell Cycle       Date:  2010-03-14       Impact factor: 4.534

8.  MycN promotes TRPM7 expression and cell migration in neuroblastoma through a process that involves polyamines.

Authors:  Ingo Lange; Dana-Lynn T Koomoa
Journal:  FEBS Open Bio       Date:  2014-10-30       Impact factor: 2.693

9.  Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells.

Authors:  Guan Wang; Holly Edwards; J Timothy Caldwell; Steven A Buck; William Y Qing; Jeffrey W Taub; Yubin Ge; Zhihong Wang
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

10.  Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma.

Authors:  Marco Lodrini; Annika Sprüssel; Kathy Astrahantseff; Daniela Tiburtius; Robert Konschak; Holger N Lode; Matthias Fischer; Ulrich Keilholz; Angelika Eggert; Hedwig E Deubzer
Journal:  Oncotarget       Date:  2017-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.